PolyProx’s technology offers the potential to broaden the druggable proteome, encompassing a range of highly validated therapeutic targets for which there are no existing drugs. This exciting new company, underpinned by world-class science and deep intellectual property, is a fantastic example of the type of businesses we support from the Cambridge ecosystem. We look forward to working with PolyProx’s experienced team as the company advances.
Professor Laura Itzhaki, Founder and Chief Scientific Officer of PolyProx Therapeutics, commented, “We are thrilled to have closed the seed round which will enable us to grow the PolyProx team and develop our technology further over the next two years. Our platform, which harnesses the cell’s natural protein degradation pathways, should allow access to many hard-to-drug targets and allow us to screen our molecules against these targets much more quickly than existing approaches. We are excited to continue the discovery process in our labs at the Babraham Research Campus, as we enter the next phase of our development.”
Christine Martin, Investment Manager at Cambridge Enterprise, said, “It is exciting to help spin out Professor Itzhaki’s outstanding and impactful research from the University. This is a great technology that is poised to address the elusive ‘difficult to drug’ section of the proteome to ultimately bring patient benefit.”